Do you want to read an article? Please log in or register.
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
Myocardial InfarctionThrombosis and Stroke
Related content
Heart, Artery and Coronary Diseases
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial
Lancet.
Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, Metsarinne K, O'Donnell M, Dans AL, Ha JW, Parkhomenko AN, Avezum AA, Lonn E, Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori M, Yusoff K, Guzik TJ, Bhatt DL, Branch KRH, Cook Bruns N, Berkowitz SD, Anand SS, Varigos JD, Fox KAA, Yusuf S; COMPASS investigators
doi: 10.1016/S0140-
Heart, Artery and Coronary DiseasesMyocardial InfarctionThrombosis and Stroke
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
Lancet.
Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S; COMPASS Investigators
doi: 10.1016/S0140-
Cardiovascular Risk and Diseases
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial
Eur Heart J.
de Vries TI, Eikelboom JW, Bosch J, Westerink J, Dorresteijn JAN, Alings M, Dyal L, Berkowitz SD, van der Graaf Y, Fox KAA, Visseren FLJ
doi: 10.1093/eurheartj/ehz404.
RECOMMENDED
Cardiovascular Risk and DiseasesTherapy and Intervention
Polypill with or without Aspirin in Persons without Cardiovascular Disease
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
N Engl J Med
Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, López-Jaramillo P, Yusoff K, Santoso A, Gamra H, Talukder S, Christou C, Girish P, Yeates K, Xavier F, Dagenais G, Rocha C, McCready T, Tyrwhitt J, Bosch J, Pais P, International Polycap Study 3 Investigators.
doi: 10.1056/NEJMoa2028220
Thrombosis and StrokeFurther Publications
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial
J Am Coll Cardiol.
Fox KAA, Eikelboom JW, Shestakovska O, Connolly SJ, Metsarinne KP, Yusuf S
doi: 10.1016/j.jacc.2019.02.048.
Heart, Artery and Coronary DiseasesThrombosis and Stroke
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin
J Am Coll Cardiol.
Eikelboom JW, Bosch JJ, Connolly SJ, Shestakovska O, Dagenais GR, Hart RG, Leong DP, O'Donnell M, Fox KAA, Bhatt DL, Cairns JA, Tasto C, Berkowitz SD, Cook Bruns N, Muehlhofer E, Diaz R, Maggioni AP, Yusuf S
doi: 10.1016/j.jacc.2019.07.065.
RECOMMENDED
Heart, Artery and Coronary Diseases
The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared to Aspirin in Patients Chronic Vascular Disease
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
doi: 10.1161/CIRCULATIONAHA.120.046048.
Cardiovascular Risk and Diseases
Prognostic Value of the CHADS2 Score for Adverse Cardiovascular Events in Coronary Artery Disease Patients Without Atrial Fibrillation-A Multi-Center Observational Cohort Study
J Am Heart Assoc.
Tabata N, Yamamoto E, Hokimoto S, Yamashita T, Sueta D, Takashio S, Arima Y, Izumiya Y, Kojima S, Kaikita K, Matsui K, Fujimoto K, Sakamoto K, Shimomura H, Tsunoda R, Hirose T, Nakamura N, Sakaino N, Nakamura S, Yamamoto N, Matsumura T, Kajiwara I, Koide S, Sakamoto T, Nakao K, Oshima S, Tsujita K; Kumamoto Intervention Conference Study (KICS) Investigators
doi: 10.1161/JAHA.117.006355.
Cardiovascular Risk and Diseases
The rise and fall of aspirin in the primary prevention of cardiovascular disease
Lancet.
Raber I, McCarthy CP, Vaduganathan M, Bhatt DL, Wood DA, Cleland JGF, Blumenthal RS, McEvoy JW
doi: 10.1016/S0140-6736(19)30541-0.